Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fisher, Dina
ASTERoiD, NCT03474029: Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI	Recruiting	2/3	3400	Canada, US, RoW	Rifapentine daily for 6 weeks, priftin, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks	Centers for Disease Control and Prevention, British Medical Research Council	Latent Tuberculosis	12/29	12/29
Dwilow, Rachel
NCT06498414: An Adaptive Trial to Find the Safest and Shortest TB Preventive Regimens.	Not yet recruiting	2/3	1800	Canada, RoW	rifampin standard arm, 4R10, rifampin double dose, 2R20, levofloxacin and rifapentine, 1LP	McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR)	Tuberculosis Infection, Latent	04/27	06/29